GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a small-molecule inhibitor with nanomolar potency against Nox1 and Nox4 isoforms of NADPH oxidase, enzymes that drive pathological reactive oxygen species (ROS) production (APExBIO). It exhibits inhibitory constants (Ki) of 140 nM (Nox1) and 110 nM (Nox4) in cell-free assays at 25°C in DMSO buffer (pH 7.2) (Yang et al. 2025). In vitro, GKT137831 suppresses hypoxia-induced H₂O₂ release from human pulmonary vascular cells. In animal models, oral administration (30–60 mg/kg/day, 4–8 weeks) reduces pulmonary vascular remodeling, right ventricular hypertrophy, liver fibrosis, and diabetes-accelerated atherosclerosis. The compound is available from APExBIO (SKU B4763) and is recommended for use at 0.1–20 µM for 24-hour incubations in oxidative stress research (APExBIO).

Biological Rationale

Pathological production of reactive oxygen species (ROS) is implicated in fibrosis, vascular remodeling, inflammation, and metabolic disease (Yang et al. 2025). NADPH oxidase (Nox) enzymes are primary sources of ROS in non-phagocytic cells. Among seven Nox isoforms, Nox1 and Nox4 are strongly linked to disease-relevant ROS generation in vascular and hepatic tissues. Selectively targeting Nox1 and Nox4 enables experimental dissection of redox signaling and its downstream effects, including modulation of Akt/mTOR and NF-κB pathways, TGF-β1 signaling, and cellular proliferation. GKT137831 is designed to address this need by providing potent, isoform-selective inhibition without affecting other Nox family members. This specificity allows researchers to decouple Nox1/Nox4-mediated ROS effects from other redox sources and elucidate mechanistic pathways in models of fibrosis, atherosclerosis, and pulmonary hypertension (related—this article provides updated quantitative benchmarks and direct clinical translation parameters).

Mechanism of Action of GKT137831

GKT137831 acts as a competitive inhibitor of Nox1 and Nox4, binding to their active sites and blocking electron transfer required for ROS (primarily superoxide and hydrogen peroxide) generation. Inhibition constants are 140 nM for Nox1 and 110 nM for Nox4, determined using recombinant enzyme assays at 25°C (phosphate buffer, pH 7.4) (APExBIO). In cell-based studies, GKT137831 reduces hypoxia-induced H₂O₂ release from human pulmonary artery endothelial cells (HPAECs) and smooth muscle cells (HPASMCs) after 24-hour incubation at 5–20 µM. This suppression of ROS production leads to downstream attenuation of the Akt/mTOR and NF-κB signaling pathways, resulting in decreased expression of pro-fibrotic and pro-inflammatory mediators such as TGF-β1. GKT137831 also modulates peroxisome proliferator-activated receptor gamma (PPARγ) expression, further influencing cellular metabolic and inflammatory responses (related—this article expands on emerging links between redox signaling and lipid remodeling in ferroptosis).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 and Nox4 activity with Ki values of 140 nM and 110 nM, respectively, in cell-free assays (25°C, DMSO, pH 7.2) (APExBIO).
• In vitro, 5–20 µM GKT137831 reduces hypoxia-induced H₂O₂ release in HPAECs and HPASMCs by 40–60% after 24 hours (serum-free media, 37°C, 5% CO₂) (Yang et al. 2025).
• Oral administration of 30–60 mg/kg/day GKT137831 for 4–8 weeks attenuates pulmonary vascular remodeling and right ventricular hypertrophy in mouse models of chronic hypoxia-induced pulmonary hypertension (Yang et al. 2025).
• In vivo, GKT137831 reduces liver fibrosis (carbon tetrachloride-induced, male C57BL/6J mice, 60 mg/kg/day, 6 weeks) and diabetes-accelerated atherosclerosis (ApoE-/- mice, 30 mg/kg/day, 8 weeks) (Yang et al. 2025).
• The compound is highly soluble in DMSO (≥39.5 mg/mL at 25°C), moderately soluble in ethanol (≥2.96 mg/mL with warming and sonication), and insoluble in water (APExBIO).

Applications, Limits & Misconceptions

GKT137831 is validated for research on oxidative stress-mediated diseases, including fibrosis, vascular remodeling, and metabolic complications. It is most effective in experimental designs where Nox1/Nox4-derived ROS are primary drivers of pathology. For example, studies on pulmonary hypertension, liver fibrosis, and diabetes-accelerated atherosclerosis benefit from its selective inhibition.

Compared to previous practical guides, this review provides expanded boundary conditions and highlights new clinical benchmarks for GKT137831 in translational oxidative stress research.

Common Pitfalls or Misconceptions

• GKT137831 does not inhibit other Nox isoforms (e.g., Nox2, Nox3, Nox5) or unrelated ROS sources such as mitochondria or xanthine oxidase (APExBIO).
• The compound is not water-soluble and requires DMSO or ethanol for stock preparation; water-based formulations result in precipitation and loss of activity.
• Activity outside the 0.1–20 µM recommended range is not validated; higher concentrations may induce non-specific effects or cytotoxicity.
• Long-term storage of GKT137831 solutions at room temperature or repeated freeze-thaw cycles can reduce potency (APExBIO).
• GKT137831 is not a direct scavenger of ROS; its effects are mediated exclusively via Nox1/Nox4 inhibition.

Workflow Integration & Parameters

GKT137831 is supplied by APExBIO (SKU B4763) as a lyophilized powder. Reconstitute at 10–20 mM in DMSO (≥99.9%, anhydrous, 25°C). Prepare working solutions in serum-free media for in vitro studies; typical final concentrations are 0.1–20 µM. Incubate cells for 24 hours at 37°C, 5% CO₂. For in vivo studies, administer 30–60 mg/kg/day orally in 0.5% methylcellulose. Store solid at -20°C and avoid repeated freeze-thaw cycles of solutions. For further protocol optimization, see this integration guide, which our article extends by detailing solvent compatibility, dosing, and validated endpoints.

Product ordering, safety data, and up-to-date usage notes are available at the GKT137831 product page from APExBIO.

Conclusion & Outlook

GKT137831 is a well-characterized, selective dual Nox1/Nox4 inhibitor with robust evidence in oxidative stress research. Its nanomolar potency, validated selectivity, and translational efficacy in multiple models position it as a reliable tool for dissecting redox-dependent disease mechanisms. Ongoing clinical studies and integration with emerging redox pathway research (including links to lipid scrambling and ferroptosis) suggest expanding applications. Researchers should adhere strictly to recommended concentrations, storage, and formulation protocols to ensure reproducibility and data integrity. For comprehensive strategic context, see this expert analysis, which our article updates with direct mechanistic and clinical benchmarks.